Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
182.99
+5.64 (3.18%)
Apr 20, 2026, 12:27 PM EDT - Market open
Biogen Employees
Biogen had 7,500 employees as of December 31, 2025. The number of employees decreased by 105 or -1.38% compared to the previous year.
Employees
7,500
Change (1Y)
-105
Growth (1Y)
-1.38%
Revenue / Employee
$1,318,747
Profits / Employee
$172,387
Market Cap
26.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,500 | -105 | -1.38% |
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
BIIB News
- 3 hours ago - Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters
- 4 hours ago - Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - GlobeNewsWire
- 2 days ago - These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. - Market Watch
- 13 days ago - Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform - Business Wire
- 20 days ago - Why This Pharma Stock More Than Doubled Today - Barrons
- 20 days ago - Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases - Market Watch
- 20 days ago - Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion - WSJ
- 20 days ago - Biogen to buy Apellis Pharmaceuticals for $5.6 billion - Reuters